Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT
7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS
7.1 REGULATORY SCENARIO IN THE U.S
7.2 REGULATORY SCENARIO IN AUSTRALIA
7.3 REGULATORY SCENARIO IN JAPAN
7.4 REGULATORY SCENARIO IN CHINA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER
8.1.3 IMPROVED IMAGING TECHNIQUES
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS
8.3 OPPORTUNITIES
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC
8.3.3 RISING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 CT SCAN
9.2.2 MRI
9.2.3 PET
9.2.4 OTHERS
9.3 MOLECULAR TESTING
9.4 ELECTROENCEPHALOGRAPHY (EEG)
9.5 LUMBAR PUNCTURE
9.6 BIOPSY
9.6.1 OPEN BIOPSY
9.6.2 STEREOTACTIC BIOPSY
9.6.3 NEEDLE BIOPSY
9.6.4 NEUROENDOSCOPY
9.7 OTHERS
10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 GLIOBLASTOMA MULTIFORME
10.3 MENINGIOMAS
10.4 ASTROCYTOMAS
10.5 ACOUSTIC NEUROMA
10.6 OLIGODENDROGLIOMA
10.7 OLIGODENDROGLIOMA
10.8 OTHERS
11 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 35-65
11.3 65 AND ABOVE
11.4 BELOW 21
11.5 21-34
12 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES
12.5 AMBULATORY SURGICAL CENTERS
12.6 OTHERS
13 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE
16.1 KONINKLIJKE PHILIPS N.V.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 CANON INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 SIEMENS HEALTHCARE GMBH
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NIHON KOHDEN CORPORATION.
16.5.1 COMPANY SNAPSHOT
16.5.2 RECENT FINANCIALS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOCEPT, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOMIND
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CEREBRAL DIAGNOSTIC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DXCOVER LIMITED
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 FONAR CORP.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 FUJIFILM CORPORATION
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GE HEALTHCARE.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 HITACHI, LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MINFOUND MEDICAL SYSTEMS CO.,
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NANTOMICS.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 NEUSOFT CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SEQUOIA HEALTHCARE.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 STERNMED GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 THERMO FISHER SCIENTIFIC INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 35 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET
FIGURE 14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 15 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022
FIGURE 19 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022
FIGURE 23 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
